​

Conduit Pharmaceuticals Stock (NASDAQ:CDT)

RevenueOwnershipFinancialsChart

Previous Close

$0.62

52W Range

$0.51 - $350.00

50D Avg

$1.22

200D Avg

$13.25

Market Cap

$10.22M

Avg Vol (3M)

$4.83M

Beta

2.35

Div Yield

-

CDT Company Profile

Conduit Pharmaceuticals Inc. operates as a clinical stage specialty biopharmaceutical company that provides unmet medical needs in the areas of autoimmune disease and idiopathic male infertility. It's pipeline includes AZD1656 for the treatment of hashimoto's thyroiditis, renal transplant, uveitis, and preterm labor; and AZD5904 for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 28, 2022

Website

CDT Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceSep 24Jun 24Mar 24
Americas$440.08M$399.79M$349.22M
Asia Pacific$81.63M$79.15M$62.91M
EMEA$133.21M$125.40M$123.54M

Fiscal year ends in Dec 24 | Currency in USD

CDT Financial Summary

Dec 24Dec 23Dec 22
Revenue$2.46B--
Operating Income$266.46M$-5.56M$-3.16M
Net Income$198.43M$-535.00K$-4.89M
EBITDA$266.46M$-324.00K$-1.43M
Basic EPS$4.88$-0.18$-0.56
Diluted EPS$4.80$-0.18$-0.56

Fiscal year ends in Dec 24 | Currency in USD